Quantum biopharma receives final reports for two key studies of its potential breakthrough drug for multiple sclerosis, moving closer to phase 2 clinical trial

Toronto, oct. 02, 2025 (globe newswire) -- quantum biopharma ltd. (nasdaq: qntm) (cse: qntm) (fra: 0k91) (upstream: qntm) (“quantum biopharma” or the “company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, is pleased to announce today that it has received two key final reports related to its potential breakthrough drug for multiple sclerosis: the 90-day oral toxicity study report and the toxicokinetic study report for lucid-21-302 (“lucid-ms”). these studies were commissioned to provide key data to support an investigational new drug (ind) application with the us fda for a phase-2 clinical trial in multiple sclerosis.
QNTM Ratings Summary
QNTM Quant Ranking